Quantum Cyber (QUCY) Registration Filing summary

Company overview and business model

• Develops and sells in-vitro diagnostic (IVD) tests for early cancer detection, with a focus on colorectal and pancreatic cancer.

• Flagship product, ColoAlert, is CE-IVD certified and marketed in Europe; next-generation mRNA-based CRC screening test in development for US and EU launch.

• Pursues partnerships with labs and healthcare providers to expand market reach, especially in Germany and other European countries.

• Engaged in R&D projects, including PancAlert for pancreatic cancer and collaborations for biomarker discovery.

• Implements AI and machine learning to enhance diagnostic accuracy.

Financial performance and metrics

• Reported revenues of $893,991 in 2024 and $895,479 in 2023.

• Operating loss of $18.7 million in 2024, down from $26.6 million in 2023, reflecting cost reduction measures.

• Cash balance as of December 31, 2024 was $6.2 million, with total assets of $13.2 million and total liabilities of $7.2 million.

• Working deficit of $1.9 million and total stockholders' equity of $6.0 million as of year-end 2024.

Use of proceeds and capital allocation

• Net proceeds of approximately $5.33 million (assuming full offering) intended for the eAArly Detect 2 study, next-generation product development, commercial expansion of ColoAlert, debt repayment, and general corporate purposes.

• Management has broad discretion in the application of proceeds.